Kura Oncology Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	104.03	53.88	-	-	-	-
Cost of Revenue	224.31	155.35	-	-	-	-
Gross Profit	-120.28	-101.46	-	-	-	-
Selling, General & Admin	104.91	77.11	50.57	47.05	46.54	31.5
Research & Development	14.62	14.62	115.24	92.81	84.72	60.4
Operating Expenses	119.53	91.73	165.8	139.87	131.26	91.9
Operating Income	-239.82	-193.2	-165.8	-139.87	-131.26	-91.9
Interest Expense	-1.57	-1.62	-1.55	-0.23	-0.41	-0.58
Interest & Investment Income	13.61	9.71	5.3	5.86	5.6	3.26
EBT Excluding Unusual Items	-227.78	-185.11	-162.05	-134.23	-126.08	-89.22
Gain (Loss) on Sale of Investments	13.14	13.14	9.42	-1.61	-4.39	-0.41
Pretax Income	-214.64	-171.97	-152.63	-135.84	-130.47	-89.63
Income Tax Expense	2.24	2.02	-	-	-	-
Net Income	-216.88	-173.98	-152.63	-135.84	-130.47	-89.63
Net Income to Common	-216.88	-173.98	-152.63	-135.84	-130.47	-89.63
Shares Outstanding (Basic)	87	86	73	67	66	53
Shares Outstanding (Diluted)	87	86	73	67	66	53
Shares Change (YoY)	4.45%	17.66%	9.31%	0.96%	25.01%	26.54%
EPS (Basic)	-2.48	-2.02	-2.08	-2.03	-1.97	-1.69
EPS (Diluted)	-2.48	-2.02	-2.08	-2.03	-1.97	-1.69
Free Cash Flow	83.11	133.85	-124.99	-110.69	-105.7	-72
Free Cash Flow Per Share	0.95	1.55	-1.71	-1.65	-1.59	-1.36
Gross Margin	-115.63%	-188.30%	-	-	-	-
Operating Margin	-230.53%	-358.54%	-	-	-	-
Profit Margin	-208.48%	-322.89%	-	-	-	-
Free Cash Flow Margin	79.89%	248.40%	-	-	-	-
EBITDA	-238.99	-192.35	-164.96	-139.11	-130.7	-91.71
D&A For EBITDA	0.83	0.85	0.85	0.76	0.56	0.19
EBIT	-239.82	-193.2	-165.8	-139.87	-131.26	-91.9
Revenue as Reported	104.03	53.88	-	-	-	-

Updated Nov 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q